Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

CERTIS1 : A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

One/TwoPhase One/Two

18-130Age 18-130

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Brain and spinal cord,Breast,Female reproductive organs,Stomach and upper gastrointestinal tract,Urinary systemBreast,Fallopian tube,Glioma,Ovary,Pancreas,Peritoneal,Prostate

Trial Overview Read MoreRead more

This phase I/II study is evaluating how safe, tolerable and effective a new targeted therapy (AZD9574) is alone, or in combination with chemotherapy (temozolomide) in people with advanced solid cancers.
 

This trial is treating patients with ovarian, fallopian tube or primary peritoneal cancer, breast cancer, castration-resistant prostate cancer, pancreatic cancer, and IDH1/2-mutant glioma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • Your cancer has not spread to other parts of the body.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)

Commercial Sponsor

AstraZeneca

Summary

This study has two Modules. Module 1 has two parts. In Module 1 Part 1, participants with advanced or relapsed ovarian, breast, pancreatic or prostate cancer who are suitable for a Poly ADP-Ribose Polymerase (PARPi) will receive AZD9574 (orally) as monotherapy in escalating cohorts. In Module 1 Part 2, participants with breast cancer who are PARPi naive will receive AZD9574 (orally) at a dose determined in Part 1. At this stage, Module 2 only has one part but a second part may be added in future. In Module 2 Part 1, participants with IDH 1/2-mutant glioma who are PARPi naive will receive AZD9574 (orally) and temozolomide (orally) at escalating doses.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Nathan Reader Wilson
PCCTU.EDD@petermac.org

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next